Ignite Creation Date:
2024-05-06 @ 3:53 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02393859
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2015-03-16
Brief Title:
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk HR First Relapse B-precursor Acute Lymphoblastic Leukemia ALL
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Phase 3 Trial to Investigate the Efficacy Safety and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
B-precursor ALL is an aggressive malignant disease Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse In general pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy Standard of care chemotherapy is associated with considerable toxicity There is a lack of novel treatment options for subjects who relapse or are refractory to treatment Therefore innovative therapeutic approaches are urgently needed Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells This study will evaluate the event-free survival EFS after treatment with blinatumomab when compared to standard of care SOC chemotherapy The effect of blinatumomab on overall survival and reduction of minimal residual disease compared to SOC chemotherapy will also be investigated
Detailed Description:
Patients will be randomized in a 11 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy Blinatumomab is administered as a continuous intravenous infusion CIVI One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab After completing consolidation therapy the patients should undergo alloHSCT depending on their bone marrow status The patients will be followed up until the last subject on study is 36 months following alloHSCT or has died whichever is first
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-002476-92 | EUDRACT_NUMBER | None | None |